About Telehealth NAD+.

What this site is

Telehealth NAD+ is an independent editorial project that publishes summaries of the peer-reviewed research literature on NAD+ (nicotinamide adenine dinucleotide) and its precursors. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product — no supplements, no infusions, no injections. Our work is editorial commentary on publicly available science, organized as a precise readout of what specific studies measured.

We read the literature with one discipline above all: the coenzyme NAD+ is kept distinct from its precursors NMN and NR, and a trial of an oral precursor is never described as "taking NAD+." Where the evidence is strong — that precursors raise blood NAD+ — we say so. Where it is weak — hard clinical outcomes, IV efficacy — we say that too, in the same plain register.

About the word "telehealth" in our name

The "telehealth" in this site's name is editorial framing, not a description of a service. We do not offer telehealth visits, consultations, prescriptions, or any pathway to obtain a product. NAD+ is not an FDA-approved drug, and no legitimate "prescription NAD+" telehealth pathway is implied here. The name marks the position this publisher occupies relative to the literature — a remote, plain-language readout of the science — not a claim that we connect anyone to care or commerce. If you are looking to buy or be prescribed anything, this is the wrong place: there is nothing here to purchase.

How we handle sources

Every quantitative claim on this site — every dose, percentage, duration and effect size — maps to a numbered citation in our cited references, drawn from PubMed-indexed journals including Science, Cell Metabolism, GeroScience, Scientific Reports, Nature Reviews Molecular Cell Biology and Nature Metabolism. We summarize findings; we do not extrapolate beyond them. Regulatory statements — that NAD+ is sold as a supplement, that NMN's supplement status is contested by the FDA, that a compounded injectable NAD+ product drew a Class I recall — are reported as matters of public record, not as endorsements or warnings about any specific product. We name no commercial supplement brand as a recommendation; where a brand appears, it is inside a journal citation's own title, reproduced verbatim, and nothing more. When the evidence is uncertain, we leave it uncertain rather than rounding it up into a claim.